We are analyzing https://link.springer.com/article/10.1186/cc6187.

Title:
Targeting RAGE in sepsis | Critical Care
Description:
The receptor of advanced glycation endproducts (RAGE) is a multiligand receptor that upon activation causes sustained activation of multiple inflammatory pathways. Recent evidence, summarized in a review by Bopp and colleagues in this issue of Critical Care, has implicated RAGE as a potential therapeutic target in sepsis. Here, we discuss several open issues that need to be addressed before anti-RAGE strategies can enter the sepsis clinical trial arena.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don't see any clear sign of profit-making.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

rage, sepsis, pubmed, article, google, scholar, cas, van, receptor, activation, target, hmgb, care, therapeutic, receptors, mice, endotoxin, privacy, cookies, research, critical, zoelen, advanced, glycation, immune, highmobility, group, inhibition, central, amsterdam, information, publish, search, marieke, poll, inflammatory, clinical, nuclear, endogenous, inflammation, box, nfκb, studies, ragedeficient, lethality, due, authors, shock, experimental, bierhaus,

Topics {✒️}

van der poll pattern recognition receptor polymicrobial sepsis caused excessive nf-κb activation imminent danger rage-deficient mice injected anti-hmgb1 antibody protected cecal ligation high-dose endotoxin = cecal ligation anti-hmgb1 treatment caused privacy choices/manage cookies nuclear factor-kappa = nuclear factor-kappa academic medical center advanced glycation endproducts additional survival benefit uncontrolled hyperinflammatory response adaptive immune response promising therapeutic target european economic area multiple inflammatory pathways cell types involved hallmark study published β2-integrin mac-1 endotoxin shock [7] notably toll immune suppression evolves n-terminal domain academic medical centeruniversity authors identifying rage innate immune system wild-type mice warrants clinical trials anti-rage strategies article number 103 inflammatory cell recruitment critical care anti-rage treatment sepsis commentary published rage-deficient mice rage deficiency resulted accepting optional cookies article cite endogenous molecules sepsis implicating mortality reversing established sepsis potential therapeutic target conditions privacy policy targeting rage

Questions {❓}

Bierhaus A, Stern DM, Nawroth PP: RAGE in inflammation: a new therapeutic target?
Morbini P, Villa C, Campo I, Zorzetto M, Inghilleri S, Luisetti M: The receptor for advanced glycation end products and its ligands: a new inflammatory pathway in lung disease?
Which questions remain to be answered to further establish a role for RAGE in sepsis and to obtain further support for the notion that RAGE may be a therapeutic target in this syndrome?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Targeting RAGE in sepsis
         description:The receptor of advanced glycation endproducts (RAGE) is a multiligand receptor that upon activation causes sustained activation of multiple inflammatory pathways. Recent evidence, summarized in a review by Bopp and colleagues in this issue of Critical Care, has implicated RAGE as a potential therapeutic target in sepsis. Here, we discuss several open issues that need to be addressed before anti-RAGE strategies can enter the sepsis clinical trial arena.
         datePublished:2008-01-11T00:00:00Z
         dateModified:2008-01-11T00:00:00Z
         pageStart:1
         pageEnd:2
         sameAs:https://doi.org/10.1186/cc6187
         keywords:
            Cecal Ligation
            Endotoxin Shock
            Polymicrobial Sepsis
            Endogenous Molecule
            Imminent Danger
            Intensive / Critical Care Medicine
            Emergency Medicine
         image:
         isPartOf:
            name:Critical Care
            issn:
               1364-8535
            volumeNumber:12
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Marieke AD van Zoelen
               affiliation:
                     name:Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical CenterUniversity of Amsterdam
                     address:
                        name:Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical CenterUniversity of Amsterdam, Amsterdam, Netherlands
                        type:PostalAddress
                     type:Organization
                     name:Center for Experimental and Molecular Medicine (CEMM), Academic Medical Center,University of Amsterdam
                     address:
                        name:Center for Experimental and Molecular Medicine (CEMM), Academic Medical Center,University of Amsterdam, Amsterdam, Netherlands
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Tom van der Poll
               affiliation:
                     name:Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical CenterUniversity of Amsterdam
                     address:
                        name:Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical CenterUniversity of Amsterdam, Amsterdam, Netherlands
                        type:PostalAddress
                     type:Organization
                     name:Center for Experimental and Molecular Medicine (CEMM), Academic Medical Center,University of Amsterdam
                     address:
                        name:Center for Experimental and Molecular Medicine (CEMM), Academic Medical Center,University of Amsterdam, Amsterdam, Netherlands
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Targeting RAGE in sepsis
      description:The receptor of advanced glycation endproducts (RAGE) is a multiligand receptor that upon activation causes sustained activation of multiple inflammatory pathways. Recent evidence, summarized in a review by Bopp and colleagues in this issue of Critical Care, has implicated RAGE as a potential therapeutic target in sepsis. Here, we discuss several open issues that need to be addressed before anti-RAGE strategies can enter the sepsis clinical trial arena.
      datePublished:2008-01-11T00:00:00Z
      dateModified:2008-01-11T00:00:00Z
      pageStart:1
      pageEnd:2
      sameAs:https://doi.org/10.1186/cc6187
      keywords:
         Cecal Ligation
         Endotoxin Shock
         Polymicrobial Sepsis
         Endogenous Molecule
         Imminent Danger
         Intensive / Critical Care Medicine
         Emergency Medicine
      image:
      isPartOf:
         name:Critical Care
         issn:
            1364-8535
         volumeNumber:12
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Marieke AD van Zoelen
            affiliation:
                  name:Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical CenterUniversity of Amsterdam
                  address:
                     name:Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical CenterUniversity of Amsterdam, Amsterdam, Netherlands
                     type:PostalAddress
                  type:Organization
                  name:Center for Experimental and Molecular Medicine (CEMM), Academic Medical Center,University of Amsterdam
                  address:
                     name:Center for Experimental and Molecular Medicine (CEMM), Academic Medical Center,University of Amsterdam, Amsterdam, Netherlands
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Tom van der Poll
            affiliation:
                  name:Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical CenterUniversity of Amsterdam
                  address:
                     name:Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical CenterUniversity of Amsterdam, Amsterdam, Netherlands
                     type:PostalAddress
                  type:Organization
                  name:Center for Experimental and Molecular Medicine (CEMM), Academic Medical Center,University of Amsterdam
                  address:
                     name:Center for Experimental and Molecular Medicine (CEMM), Academic Medical Center,University of Amsterdam, Amsterdam, Netherlands
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Critical Care
      issn:
         1364-8535
      volumeNumber:12
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical CenterUniversity of Amsterdam
      address:
         name:Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical CenterUniversity of Amsterdam, Amsterdam, Netherlands
         type:PostalAddress
      name:Center for Experimental and Molecular Medicine (CEMM), Academic Medical Center,University of Amsterdam
      address:
         name:Center for Experimental and Molecular Medicine (CEMM), Academic Medical Center,University of Amsterdam, Amsterdam, Netherlands
         type:PostalAddress
      name:Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical CenterUniversity of Amsterdam
      address:
         name:Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical CenterUniversity of Amsterdam, Amsterdam, Netherlands
         type:PostalAddress
      name:Center for Experimental and Molecular Medicine (CEMM), Academic Medical Center,University of Amsterdam
      address:
         name:Center for Experimental and Molecular Medicine (CEMM), Academic Medical Center,University of Amsterdam, Amsterdam, Netherlands
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Marieke AD van Zoelen
      affiliation:
            name:Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical CenterUniversity of Amsterdam
            address:
               name:Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical CenterUniversity of Amsterdam, Amsterdam, Netherlands
               type:PostalAddress
            type:Organization
            name:Center for Experimental and Molecular Medicine (CEMM), Academic Medical Center,University of Amsterdam
            address:
               name:Center for Experimental and Molecular Medicine (CEMM), Academic Medical Center,University of Amsterdam, Amsterdam, Netherlands
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Tom van der Poll
      affiliation:
            name:Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical CenterUniversity of Amsterdam
            address:
               name:Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical CenterUniversity of Amsterdam, Amsterdam, Netherlands
               type:PostalAddress
            type:Organization
            name:Center for Experimental and Molecular Medicine (CEMM), Academic Medical Center,University of Amsterdam
            address:
               name:Center for Experimental and Molecular Medicine (CEMM), Academic Medical Center,University of Amsterdam, Amsterdam, Netherlands
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical CenterUniversity of Amsterdam, Amsterdam, Netherlands
      name:Center for Experimental and Molecular Medicine (CEMM), Academic Medical Center,University of Amsterdam, Amsterdam, Netherlands
      name:Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical CenterUniversity of Amsterdam, Amsterdam, Netherlands
      name:Center for Experimental and Molecular Medicine (CEMM), Academic Medical Center,University of Amsterdam, Amsterdam, Netherlands

External Links {🔗}(69)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

3.7s.

LINK . SPRINGER . COM {}